New Device Allows Handheld Screening for Diabetic Retinopathy

By
 
Product:
RETeval
Top Line: Access to diabetic retinopathy (DR) screenings by global populations is now much easier. LKC Technologies' RETeval, on display at the recent 2013 American Academy of Ophthalmology meeting, is a handheld DR screening device that enables virtually any health care provider to screen for and detect sight-threatening DR.
Close Up: Currently, DR screenings are done either by photographing the back of the eye and assessing the images or by an ophthalmologist/optometrist looking for visible signs of DR during a dilated eye examination. In contrast, RETeval is a functional test of the retina to assess the ischemic level of the retina which, based upon published literature, correlates well to DR and other ischemic diseases such as Central Retinal Vein Occlusion, Birdshot and others. RETeval is fast, easy to use and provides immediate results at a very low cost without dilation.
Vital Stats: RETeval is CE marked and already approved in Canada and Japan and is being used in a number of countries such as India, Indonesia, Malaysia, Japan and the U.K. For the U.S., Datovech notes that it is not yet approved by the FDA for clinical use, "We are in the process of developing the clinical data necessary to submit for FDA approval."
LKC Technologies is pursuing creative means such as strategic distribution relationships and the potential of symbiotic relations with companies that have similar interests in ischemia and DR treatment.
www.lkc.com